



22 December 2025

ASX ANNOUNCEMENT

CONNEQT Health Completes \$3.1m Institutional Placement to Support Pulse Sales Growth

Not for release to US wire services or distribution in the United States

CONNEQT Health Limited (ASX: CQT) (“CONNEQT” or “the Company”) is pleased to announce it has secured firm commitments to raise \$3.1 million (before costs) through a placement of new fully paid ordinary shares (“Shares”) at \$0.045 per share to institutional and sophisticated investors (the “Placement”).

The Placement was well supported by new and existing institutional shareholders, together with strong support from sophisticated investors. C2 Ventures Pty Limited (“C2V”), the Company’s largest shareholder (and a company owned by directors Craig Cooper and Niall Cairns) will also participate in the Placement to subscribe for \$1.2 million worth of Placement Shares. The issue of the Placement Shares to C2V is subject to shareholder approval at the Company’s next general meeting.

The Placement price of \$0.045 per share represents a 15.1% discount to the last closing price on 18 December 2025, and a 6.3% discount to the Company’s 15-day volume weighted average price (VWAP) at the close of trading on 18 December 2025 of \$0.053.

The Company will issue 42,222,220 shares under the Company’s ASX Listing Rule 7.1 placement capacity on Wednesday, 31 December 2025, and 26,666,666 Shares will be issued to C2V subject to shareholder approval at the Company’s next general meeting and will not be issued under the Company’s available placement capacity. All Shares issued under the Placement will rank equally with existing ordinary shares from the date of issue.

Stralis Capital Partners Limited acted as sole Lead Manager to the Placement and will receive fees comprising:

- (a) 3% of the Gross Proceeds under the Placement as management fee; and
- (b) 3% of the Gross Proceeds under the Placement as selling fee;

“Gross Proceeds” refers to the total amount raised under the Placement, except that (b) excludes Placement proceeds resulting from the participation of C2V and any other directors of the Company (if applicable).

CONNEQT
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Sydney NSW 2000
Australia

+61 2 9874 8761



Funds raised from the Placement will be used for inventory & device manufacturing for the CONNEQT Pulse, marketing & sales activities, product development & regulatory expenses, general working capital, operations & corporate purposes, and costs of the Placement.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").